Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-actinin (ACTN)
- Target
- ACTN
- Molecular classification
- Cytoskeletal protein, Actin-binding protein, Spectrin superfamily
01
Overview
Alpha-actinin is a key member of the spectrin superfamily and acts as a principal crosslinking and anchoring protein for actin filaments in both muscle and non-muscle cells. It forms anti-parallel rod-shaped dimers, with actin-binding domains at each end, stabilizing cytoskeletal structure, especially at the Z-disk of muscle cells and in focal adhesions in non-muscle cells. In addition to actin binding, alpha-actinin interacts with adhesion and signaling proteins such as integrins, vinculin, and signaling kinases, thus regulating cytoskeletal organization, cell shape, adhesion, and signal transduction. Four human genes (ACTN1–4) code for tissue-specific isoforms, associated with distinct physiological and pathological roles. Alpha-actinin is not a direct drug target but has major functional relevance in muscle diseases, cancer, and kidney diseases due to mutations or misregulation of specific isoforms.
- Other names
- Alpha actininACTNSpectrin family actin-binding proteinActin crosslinking proteinACTN1 (isoform 1)ACTN2 (isoform 2)ACTN3 (isoform 3)ACTN4 (isoform 4)
02
Mechanism of action
Not applicable
03
Biological functions
Crosslinking and organizing actin filamentsMaintaining cytoskeletal structureSarcomere (Z-disk) stabilization in muscleCell adhesion and mechanotransductionRegulation of cell motilitySignal transduction scaffold
04
Disease associations
Muscle disorders (e.g., cardiomyopathies, muscular dystrophies)Platelet disordersRenal diseases (e.g., focal segmental glomerulosclerosis, related to ACTN4 mutations)Cancer (metastasis, especially ACTN4)Athletic performance (ACTN3, "sprinter gene")
05
Safety considerations
Essential structural function: Disrupting alpha-actinin function systemically would likely result in significant cytoskeletal, contractile, and organ toxicity.Isoform/tissue specificity challenges: Multiple isoforms with distinct tissue distribution complicate potential targeting.
06
Interacting drugs
None directly
07
Biomarkers
ACTN3 genotype (used in sports medicine, muscle disease susceptibility)ACTN4 expression (prognostic indicator in certain cancers, e.g., renal cell carcinoma)
Beyond the preview
Go deeper on Alpha-actinin (ACTN).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alpha-actinin (ACTN).